ArticleFrontiers in microbiology2026
Genomic and metabolomic insights into the antimicrobial and therapeutic potential of
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DualFoods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Probiotic candidates from underexplored ecological niches represent a valuable source of novel functional traits. This study reports, for the first time, the probiotic potential and safety profile of Methods: Whole-genome sequencing was performed followed by functional annotation, phylogenetic analysis, and biosynthetic gene cluster (BGC) prediction. Untargeted intracellular metabolomic profiling (Met-Int) was conducted using gas chromatography coupled with quadrupole time-of-flight mass spectrometry (GC/MS-QTOF). Results: Genomic analysis revealed a stable and biosafe genome (3.23 Mb) devoid of mobile virulence factors and ARGs, while encoding multiple class IIb plantaricins consistent with broad-spectrum antimicrobial activity. Metabolomic profiling identified several bioactive compounds, including phenyllactic acid, γ-aminobutyric acid, 3-(4-hydroxyphenyl)lactic acid, and benzoic acid. In vitro and Conclusion:
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.